Showing 4841-4850 of 5554 results for "".
- La Roche-Posay Foundation Opens Call for Abstractshttps://practicaldermatology.com/news/la-roche-posay-foundation-opens-call-for-abstracts/2460163/The La Roche-Posay North American Foundation has opened a call for scientific abstracts. The La Roche-Posay North American Foundation was established in 2005 to support outstanding candidates with promising projects in the field of clinical, biological or pharmacological research linked to
- Pediatric Dermatologist Who Co-Founded Camp for Children Recognized for Carehttps://practicaldermatology.com/news/pediatric-dermatologist-who-co-founded-camp-for-children-recognized-for-care/2460153/The American Academy of Dermatology honored dermatologist Karen Wiss, MD, FAAD, as a Patient Care Hero for her role in treating a patient with recessive dystrophic epidermolysis bullosa (RDEB). To support pediatric patients with isolating conditions like RDEB, Dr. Wiss, a derm
- Study: Long-Term Use of Brodalumab Is Safe, Effectivehttps://practicaldermatology.com/news/study-long-term-use-of-brodalumab-is-safe-effective/2460150/Long-term use of brodalumab (SILIQ) improved skin clearance and quality of life in patients with moderate-to-severe psoriasis, according to a new study in the American Journal of Clinical Dermatology. Ov
- Europe Grants DefenAge Skincare Master Patenthttps://practicaldermatology.com/news/europe-grants-defenage-skincare-master-patent/2460132/DefenAge Skincare now has a master patent from the European Patent Office that covers DefenAge’s core technology. The patent protects the exclusive rights of DefenAge to use the spectrum of immune peptides called defensins in topical cosmetic formulations in a specific range of co
- Cassiopea Submits NDA for New Acne Treatmenthttps://practicaldermatology.com/news/cassiopea-submits-nda-for-new-acne-treatment/2460131/Cassiopea SpA submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking marketing approval for clascoterone cream 1% for the treatment of acne. Clascoterone cream 1% is under investigation as a first-in-class topical androgen receptor inhibitor for th
- Straight Up: Paula Abdul Is InMode's New Brand Ambassadorhttps://practicaldermatology.com/news/straight-up-paula-abdul-is-inmodes-new-brand-ambassador/2460122/Paula Abdul is InMode’s new brand ambassador for BodyTite, FaceTite and Morpheus8 technologies. As a lifelong performer, Abdul has always taken care of herself and has the muscles to prove it—however, at age 57, she acknowledg
- Nebraska Gets “SUNucated”https://practicaldermatology.com/news/nebraska-gets-sunucated/2460116/Nebraska is the latest state to recommend that children be allowed to possess and use sunscreen without a doctor’s note at school and at school-sponsored events. “I am thrilled that Nebraska is stepping up to the plate with commonsense information that will now be con
- Sciton Targets Veins, Skin, and Hair with Clear Suitehttps://practicaldermatology.com/news/sciton-targets-veins-skin-and-hair-with-clear-suite/2460111/Sciton Inc. is launching its Clear Suite family of products. The Clear Suite offerings make the JOULE platform customizable. Utilizing the 1064 Nd:YAG wavelength, the Clear Suite family of products, including ClearV, ClearSilk, and ClearHair, combined with BroadBand Light (BBL), al
- Summer AAD News: Understanding the Dermatologist’s Role in Reducing Skin-related Side Effects from New Cancer Drugshttps://practicaldermatology.com/news/summer-aad-news-understanding-the-dermatologists-role-in-reducing-skin-related-side-effects-from-new-cancer-drugs/2460107/While a new wave of targeted therapies are helping patients fight cancer, they also produce side effects that can affect patients’ hair, skin and nails that can greatly impact patients’ quality of life and threaten their ability to continue treatment. “Approximat
- Summer AAD News: Hyperhidrosis Updatehttps://practicaldermatology.com/news/summer-aad-news-hyperhidrosis-update/2460106/At least 15 million people in the U.S. experience diminished quality of life due to hyperhidrosis, yet half of people with the condition delay treatment for 10 years or more, according to information presented at the 2019 American Academy of Dermatology Summer Meeting in New York City.